![]() The FDA’s heavy focus on COVID-19 could slow the approvals on non-COVID-19 therapies. Aside from vaccines, the biotech industry is dependent on the volume of new therapy approvals. Due to this, repeat vaccinations will likely be necessary for lifelong immunity which would provide a long-lasting and significant source of revenue for lead vaccine developers. As COVID-19 variants have emerged, vaccine boosters have been offered in order to increase efficacy. Additionally, companies could see prescription growth pick up as in-person physician visits return to pre-pandemic levels. Drug sales are anticipated to have high growth, primarily driven by COVID-19 therapeutics, the continued adoption of many new and innovative therapies, a favorable M&A environment, and a low prevalence of patent expirations in 2022. The Biotechnology and Medical Research sub-industry has a positive outlook, a historically defensive sub-industry. Harpoon Therapeutics Inc does not currently pay a dividend. ![]() Analysts expect adjusted earnings to reach $-2.195 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was 43.1%. Harpoon Therapeutics Inc’s trailing 12-month revenue is $23.0 million with a -329.8% profit margin. ![]() Latest Harpoon Therapeutics Inc Stock NewsĪs of September 06, 2022, Harpoon Therapeutics Inc had a $56.3 million market capitalization, putting it in the 24th percentile of companies in the Biotechnology & Medical Research industry.Ĭurrently, Harpoon Therapeutics Inc’s price-earnings ratio is. Read on to find out how ( HARP) grades on certain investment factors and determine whether it meets your investment needs. Learn more about whether Harpoon Therapeutics Inc is a good stock to buy or sell based on recent news as well as its key financial metrics.
0 Comments
Leave a Reply. |